Arlene Weintraub

On the Brink of Generic Biotech Drugs, What's the Cost to Innovation?

... at the FDA for approving generic biotech drugs would save the United States “billions of dollars.” But, as Arlene Weintraub was quick to point out in BusinessWeek, “How many billions? And how fast would those savings be achieved?” With the ... Read